Výsledky vyhledávání - "Andreas Drangevåg"

Akademický článek

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells.

Autor: Thomas Helland, Jennifer Gjerde, Simon Dankel, Ingvild S Fenne, Linn Skartveit, Andreas Drangevåg, Olivera Bozickovic, Marianne Hauglid Flågeng, Håvard Søiland, Gunnar Mellgren, Ernst A Lien

Publikováno v: PLoS ONE, Vol 10, Iss 4, p e0122339 (2015)

INTRODUCTION:Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-dem

Externí odkaz: https://doaj.org/article/fb52e9f7d3184425ae1d8a60233d04aa

Zobrazit plný text záznamu

The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells

Autor: Olivera Bozickovic, Linn Skartveit, Marianne Hauglid Flågeng, Ernst A. Lien, Thomas Helland, Simon N. Dankel, Gunnar Mellgren, Andreas Drangevåg, Jennifer Gjerde, Ingvild S. Fenne, Håvard Søiland

Publikováno v: PLoS ONE, Vol 10, Iss 4, p e0122339 (2015)
PLoS ONE
e0122339

Introduction: Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive breast cancer. Effects and side effects of tamoxifen is the sumof tamoxifen and all itsmetabolites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-deme

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ea27fd7ccc1390a3c7705cb4a4f077
http://europepmc.org/articles/PMC4395096?pdf=render

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání